Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 2:28 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 313–336 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Completed Phase 2Phase 3 Interventional Results available

Fetal and Infant Effects of Maternal Buprenorphine Treatment

NCT01561079
View directory record Official record
Conditions
Neonatal Abstinence Syndrome
Interventions
Buprenorphine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 26, 2017 · Synced Oct 27, 2026, 2:28 PM EDT
Recruiting Phase 1 Interventional

Right Tools, Right Time, Right Place: Telehealth for Opioid Use Disorder in Vulnerable Settings

NCT07169409
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Telemedicine Buprenorphine Treatment
Drug
Lead sponsor
Boulder Care
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Impact on Opioid Use of Bundling Medication-assisted Treatment With mHealth

NCT02712034
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
MAT + A-CHESS, MAT
Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
417 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 14, 2020 · Synced Oct 27, 2026, 2:28 PM EDT
Withdrawn Not applicable Interventional

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

NCT03762798
View directory record Official record
Conditions
Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
Interventions
The Bridge
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 27, 2026, 2:28 PM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy of Buprenorphine and XR-Naltrexone Combination for Relapse Prevention in Opioid Use Disorder

NCT05011266
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine/naloxone, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
2
States / cities
Rockville, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Phase 1 Interventional

Medication-Assisted Treatment for Youth With Substance Use Disorders

NCT02593474
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Dependence
Interventions
Naltrexone
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
16 Years to 25 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2018 · Synced Oct 27, 2026, 2:28 PM EDT
Recruiting Phase 2 Interventional

E-Cigarettes for Harm Reduction in Smokers With Opioid Use Disorder

NCT05722561
View directory record Official record
Conditions
Opioid Use Disorder, Cigarette Smoking
Interventions
Telehealth Motivational Counseling, Nicotine Replacement Product, National Institute on Drug Abuse (NIDA) Standardized Research Electronic Cigarette (SREC).
Behavioral · Drug · Device
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years to 75 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
New York, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

To Test a Payer/Treatment Agency Intervention to Increase Use of Buprenorphine

NCT01702142
View directory record Official record
Conditions
Addiction
Interventions
Not listed
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
17 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Phase 3 Interventional Results available

Long-term Open-Label Safety Study to Evaluate EN3409

NCT01755546
View directory record Official record
Conditions
Low Back Pain, Osteoarthritis, Neuropathic Pain
Interventions
EN3409
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
57
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

Trial of Buprenorphine/Naloxone for Opiate Dependence - 2

NCT00000353
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine/naloxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
19 Years to 57 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 1997
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Oct 27, 2026, 2:28 PM EDT
Completed No phase listed Observational

Evaluating the SUBLOCADE Treatment Exit Strategy

NCT05878210
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Not listed
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Portland, Maine
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Terminated Phase 2 Interventional Results available

Pharmacologically-based Strategies for Opioid Substitution Therapy During Pregnancy

NCT03831113
View directory record Official record
Conditions
Opiate Addiction, Pregnancy
Interventions
Magnitude Group, Frequency Group
Drug
Lead sponsor
Steve N. Caritis, MD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 29, 2024 · Synced Oct 27, 2026, 2:28 PM EDT
Recruiting Phase 1 Interventional

Adjunctive Effects of Psilocybin and a Formulation of Buprenorphine

NCT04161066
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Psilocybin with facilitated counseling
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine Disposition and Cyclosporine

NCT01648270
View directory record Official record
Conditions
Healthy
Interventions
buprenorphine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 27, 2026, 2:28 PM EDT
Completed No phase listed Observational

Treatment Study: Reducing Cocaine/Heroin Abuse With SR-Amphetamine and Buprenorphine (ARC)

NCT00698737
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Cocaine Abuse or Dependence
Interventions
Not listed
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 22, 2012 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Not applicable Interventional Results available

Prolonged Exposure Therapy for PTSD and Opioid Use Disorder

NCT04104022
View directory record Official record
Conditions
Post Traumatic Stress Disorder, Opioid-use Disorder
Interventions
Prolonged Exposure Therapy, Attendance-based monetary incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Not applicable Interventional

Feasibility Study of Novel Prescription Digital Therapeutic Supporting Unobserved Buprenorphine Initiation & Adherence

NCT05412966
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
PEAR-002B, reSET-O
Device
Lead sponsor
Pear Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Berlin, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Oct 27, 2026, 2:28 PM EDT
Not yet recruiting Phase 1 Interventional

Buprenorphine for the Management of Pain in Children With Sickle Cell Disease

NCT07799571
View directory record Official record
Conditions
Sickle Cell Disease (SCD), Sickle Cell Disease Vaso-occlusive Crisis, Sickle Cell Anemia Crisis, Sickle Cell Anemia in Children, Sickle Cell Anemia (HbSS, or HbSβ-thalassemia0), Sickle Cell Hemoglobin C Disease, Pain Crisis
Interventions
Buprenorphine Buccal Film [Belbuca]
Drug
Lead sponsor
Natasha Archer
Other
Eligibility
12 Years to 22 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Digital Health Intervention to Support Opioid Use Disorder Treatment

NCT03842384
View directory record Official record
Conditions
Opioid Use Disorder, Treatment Adherence
Interventions
iENDURE
Behavioral
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 10, 2024 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Effects of Buprenorphine on Mood in Adults With a Range of Depressive Symptomatology

NCT02659787
View directory record Official record
Conditions
Depression
Interventions
0.2mg Buprenorphine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 35 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 27, 2026, 2:28 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Bundled Intervention

NCT06593093
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
a bundled intervention, control group
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Recruiting Early Phase 1 Interventional

A Clinical Trial Comparing Buprenorphine Formulations for High Potency Synthetic Opioid Use

NCT06726200
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine + naloxone (Suboxone), Buprenorphine Injection
Drug
Lead sponsor
Rachel R. Luba
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 27, 2026, 2:28 PM EDT
Completed Phase 2 Interventional

Emergency Department-Initiated Buprenorphine Validation Network Trial

NCT04225598
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
CAM2038, Buprenorphine Sublingual Product
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
35
States / cities
Oakland, California • San Leandro, California • New Haven, Connecticut + 25 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2025 · Synced Oct 27, 2026, 2:28 PM EDT
Terminated Phase 3 Interventional Results available

Safety and Efficacy of Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Low Back Pain

NCT00313014
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Buprenorphine, Oxycodone Immediate-Release
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
85
States / cities
Birmingham, Alabama • Haleyville, Alabama • Phoenix, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 27, 2026, 2:28 PM EDT